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Abstract Female classic galactosemia patients suffer from
primary ovarian insufficiency (POI). The cause for this
long-term complication is not fully understood. One of the
proposed mechanisms is that hypoglycosylation of complex
molecules, a known secondary phenomenon of galacto-
semia, leads to FSH dysfunction. An earlier study showed
less acidic isoforms of FSH in serum samples of two classic
galactosemia patients compared to controls, indicating
hypoglycosylation. In this study, FSH isoform patterns of
five classic galactosemia patients with POI were compared
to the pattern obtained in two patients with a primary
glycosylation disorder (phosphomannomutase-2-deficient
congenital disorders of glycosylation, PMM2-CDG) and
POI, and in five postmenopausal women as controls. We
used FPLC chromatofocussing with measurement of FSH
concentration per fraction, and discovered that there were
no significant differences between galactosemia patients,
PMM2-CDG patients and postmenopausal controls. Our
results do not support that FSH dysfunction due to a less
acidic isoform pattern because of hypoglycosylation is a
key mechanism of POI in this disease.
Introduction
Classic galactosemia (OMIM 230400), an inherited meta-
bolic disorder in galactose metabolism due to a deficiency
of galactose-1-phosphate uridyl transferase (GALT), is known
to cause glycosylation abnormalities (Charlwood et al 1998;
Dobbie et al 1990; Haberland et al 1971; Jaeken et al 1992;
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Ornstein et al 1992; Petry et al 1991; Prestoz et al 1997;
Stibler et al 1997; Sturiale et al 2005). Under a galactose-
restricted diet, these abnormalities diminish but do not
completely disappear (Charlwood et al 1998). Two main
mechanisms to explain the aberrant glycosylation have been
proposed. Classic galactosemia patients have a low UDP-
galactose/UDP-glucose ratio (Ng et al 1989), which may
influence glycoprotein and glycolipid glycan synthesis.
Furthermore, galactose-1-phosphate (Gal-1-P), one of the
metabolites that accumulates in classic galactosemia, can
inhibit galactosyltransferases and disturb glycosylation
(Lai et al 2003).
Abnormal glycosylation of FSH has been proposed as a
key mechanism in the development of primary ovarian
insufficiency (POI), one of the most prevalent and burden-
some long-term complications in galactosemic women.
Prestoz et al (1997) detected altered, less acidic isoforms of
FSH between pH 6.4 and 7.0 in three women with classic
galactosemia when compared to healthy premenopausal
women. The idea that glycosylation abnormalities of FSH
play a role in POI in galactosemia is further supported by the
fact that women with a phosphomannomutase 2-deficient
congenital disorder of glycosylation (PMM2-CDG) also have
similar early age onset hypergonadotropic hypogonadic ovarian
failure (de Zegher and Jaeken 1995; Kristiansson et al 1995).
Electrophoretic isoform patterns of FSH in CDG, however,
showed normal, acidic FSH (Kristiansson et al 1995), and
bioactivity was low-normal (de Zegher and Jaeken 1995).
In the present study, we compared the serum FSH
isoform patterns of five classic galactosemia patients with




Blood samples from five galactosemia patients (aged
between 21 and 26 years) and two PMM2-CDG patients
(both aged 33 years) with hypergonadotropic hypogonadism
and five postmenopausal women (aged 45–68 years) were
obtained under standard conditions, and serum was kept
frozen at –80°C until assayed. All women were diagnosed
with ovarian insufficiency by FSH measurements (>30 IU/l)
and clinical features (amenorrhea). The women used no
medication at the time of blood withdrawal (hormone
replacement therapy, if used, was stopped for at least 7
consecutive days before blood withdrawal). Because both
galactosemia patients and PMM2-CDG patients with POI
have biochemical (i.e. hypergonadotropic- hypoestrogenic)
postmenopausal-like features, we decided to use serum of
postmenopausal women as controls. The institutional review
board of Maastricht University Medical Center approved the
protocol as part of a larger study, and the protocol is in
accordance with the Declaration of Helsinki. After oral and
written information about the study design and protocol, the
patients signed an informed consent for this study.
Methods
We studied chromatofocusing isoform distribution patterns
of FSH according to its net charge. The analytical procedure
and the consecutive statistical analysis was described in detail
by Thomas et al. (2009). Instead of 2.5 mL serum, we used
0.5 mL serum for the present procedure. Samples and buffers
were prepared as described previously, and an Äkta FPLC
system (GE Healthcare) was equipped with a 4-mL Mono-P
5/200 GL column and equilibrated with 40 mL of startbuffer
(i.e., bis(2-hydroxyethyl)imino-tris(hydroxymethyl)methane;
bis-tris, 7.14 mM, pH 7.3-7.4). A pH gradient was generated by
introduction of elution buffer (Polybuffer 74; GE Healthcare
Biosciences, Uppsala, Sweden) used at a dilution of 1:35, pH
3.2 at a flow rate of 1.0 mL per min. After collection of 70
consecutive 2-mL effluent fractions in tubes containing
50 μL of 0.8 M phosphate buffer in 0.15 M NaCl with
0.2% NaN3 (pH 7.4), the pH was 3.2. In every fifth tube
not containing phosphate buffer, the pH was measured
manually with a pH meter (Metrohm 744; Metrohm, Herisau,
Switserland). To increase sensitivity, all the collected fractions
were concentrated 10-fold by evaporating them under
nitrogen gas at 30°C overnight. Subsequently, the dried
fractions were reconstituted in 0.2 ml ultra pure water
(Elga Ultra Pure Water System, High Wycombe, UK) and
the FSH concentrations in all individual effluent fractions
were determined with the random access analyser Architect
(Abbott, Chicago, IL, USA). The measured FSH concen-
trations in all collected effluent pH fractions were corrected
for procedural losses by taking the quantity of FSH loaded
onto the Mono-P column as 100%. From these corrected data,
we calculated the relative amounts of FSH at fixed pH values
of pH 7.0, 6.9, 6.8,…, to pH 3.0 by interpolation. In order to
test the largest discriminatory capacity between the five
galactosemia patients and the two PMM2-CDG patients with
hypergonadotropic hypogonadism and the five postmeno-
pausal women, we determined with Student’s t tests in Excel
2007 for which pH interval (i.e., the sum of the relative
amounts of FSH present in several consecutive fixed pH
fractions), the difference between the sums of the FSH
amounts in the various groups, was largest. In addition, we
calculated the mean, median and peak values (defined as the
pH interval in which the highest percentage of FSH was
found) for each group from the experimental values and
compared the obtained values using SPSS 16.0.
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Results
Figure 1 shows the average isoform pattern of each group.
It was constructed by calculating the mean value for every
interpolated pH interval per group. We did not find significant
levels of FSH isoforms in the pH 5.5–7.0 region. Statistical
comparison of the means, medians and peak values between
the galactosemia patients, CDG patients and control subjects
did not show significant differences. When comparing the
groups per pH interval, the CDG patients differed slightly
from the classic galactosemia patients and the controls in the
acidic region (pH < 4.5), but this might be caused by the small
number of CDG-PMM2 patients in this study. The classic
galactosemia patients did not significantly differ from the
control patients.
Discussion
Although some small differences between the groups are
seen, we did not find a significantly altered distribution of
FSH isoforms when comparing galactosemia patients,
PMM2-CDG patients and healthy postmenopausal controls.
The majority of FSH had a pH between 3.3 and 5.0 in all
three groups, and we did not find a significant amount of
FSH isoforms with 6.0 ≤ pH < 7.0. FSH consists of two
subunits, alpha and beta. The alpha subunit is identical to
that of three other glycoprotein hormones (LH, hCG and
TSH) and has two glycosylation sites that probably do not
contribute to bioactivity while half-life differences between
isoforms are due to compensatory mechanisms in the beta
subunit glycans. The human beta subunit has two glyco-
sylation sites, at Asn7 and Asn24, and the most common
glycans have terminal sialic acid (Dalpathado et al 2006). If
glycans are truncated, sialic acid is missing at the end,
resulting in less acidic isoforms. The observed lack of FSH-
isoforms with a pH between 6.0 and 7.0 differs from
previous results (Prestoz et al 1997). In that study, a large
band of FSH in the range of pH 6.4–7.0 on isoelectric
focussing was found. The other FSH-bands observed by
this group, between pH 3.7 and 4.4, are in accordance with
our findings, as almost all the FSH we measured was
recovered in the pH interval between 3.3 and 5.0.
The normally appearing, postmenopausal-like FSH iso-
form patterns do not favour FSH dysfunction due to
hypoglycosylation as a mechanism in the pathophysiology
of ovarian failure in classic galactosemia. This is further
supported by the finding of a similar FSH-isoform pattern
in the two PMM2-CDG patients, and by an earlier report
that shows that CDG patients have acidic isoforms rather
than more basic isoforms (Kristiansson et al 1995).
Moreover, a normal FSH bioactivity in classic galacto-
semic women (Kaufman et al 1981; Sanders et al 2008) has
been reported. The reported pregnancy following recombi-
nant FSH administration in a galactosemic woman (Menezo
et al 2004) is likely not due to rFSH overruling the inactive
endogenous FSH, but merely the stimulation of an insuffi-
ciently functioning ovary by a surplus of FSH.
In conclusion, classic galactosemic women with POI
have an FSH isoform pattern resembling that of postmen-
opausal women. Our results do not support that FSH
dysfunction due to an abnormal FSH-isoform pattern as a
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Fig. 1 Average FSH isoform
distribution pattern of classic
galactosemia patients (n=5)
compared to PMM2-CDG
patients (n=2) and postmeno-
pausal controls (n=5)
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result of hypoglycosylation is a key mechanism of POI in
classic galactosemia. Future research should focus on other
pathophysiological mechanisms underlying primary ovarian
insufficiency in classic galactosemia.
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